Leadership & Pay ·
On June 5, 2026, Axsome Therapeutics adopted an Executive Severance and Change in Control Plan
AXSMAxsome Therapeutics, Inc.
On June 5, 2026, Axsome Therapeutics adopted an Executive Severance and Change in Control Plan. The plan establishes three tiers of participants: Tier 1 (CEO), Tier 2 (Section 16 executive officers), and Tier 3 (Vice Presidents and above). Involuntary termination outside a change in control provides cash severance of 18, 12, or 6 months of base salary based on tier. Termination during a change in control period provides enhanced benefits, including increased cash severance (24, 18, or 9 months), target annual incentive payments, and 100% accelerated vesting of time-based equity awards. The company is a biopharmaceutical company that develops therapies for central nervous system disorders.